

Special Issue

Advanced Cancer Nanotheranostics

Message from the Guest Editor

Cancer is still a leading cause of death worldwide. In recent decades, nanotechnology has promoted the production of a wide set of nanoplatforms with multifunctional abilities for tumor targeting, drug loading, and controlled release. Furthermore, imaging functionalities have been coupled to these nanoplatforms, thus enabling the possibility to also diagnose cancer and monitor therapeutic progression non-invasively and in real time. Such a fusion of therapy and diagnosis promoted by nanostructured materials is known as 'nanotheranostics', and these multifunctional nanotools have encountered a great applicability in biomedicine and especially in the medical management of a lot of cancers. This Special Issue will highlight the current state of the art in the exciting and highly promising area of cancer nanotheranostics.

Guest Editor

Prof. Dr. Marco Filice

Nanobiotechnology for Life Sciences Group, Department of Chemistry in Pharmaceutical Sciences, Faculty of Pharmacy, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, E-28040 Madrid, Spain

Deadline for manuscript submissions

closed (20 October 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/92306

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)